person · Reporting owner

Ellingson Rachel

Disclosed activity across 3 companies

Tapewire entity: 64609
SEC CIK: 0001557271

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ZIMMER BIOMET HOLDINGS, INC.ZBH · Entity 3278	Chief Administrative Officer	February 20, 2025	February 24, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ZIMMER BIOMET HOLDINGS, INC.

Report date February 20, 2025 · Filed February 24, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	11,906	Ending reported balance After 2025-02-20 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2025-02-20 · Exercise / conversion · Acquired 1,566 · Balance 12,397 Row 2 · 2025-02-20 · Tax withholding · Disposed 491 · Balance 11,906 F1: Represents shares withheld by Zimmer Biomet Holdings, Inc. (the "Company") to satisfy tax withholding obligations on the vesting of restricted stock units ("RSUs").
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	3,131	Reported balance After 2025-02-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-02-20 · Exercise / conversion · Disposed 1,566 · Balance 3,131 F2: Each RSU represents a contingent right to receive one share of Company common stock. F3: One-third of the RSUs vested on February 20, 2025. The remaining RSUs vest one-half on each of February 20, 2026 and February 20, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares withheld by Zimmer Biomet Holdings, Inc. (the "Company") to satisfy tax withholding obligations on the vesting of restricted stock units ("RSUs").

F2: Each RSU represents a contingent right to receive one share of Company common stock.

F3: One-third of the RSUs vested on February 20, 2025. The remaining RSUs vest one-half on each of February 20, 2026 and February 20, 2027.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

BIOLIFE SOLUTIONS INC

Report date October 06, 2026 · Filed October 09, 2026

Section 16 reporting ended · disclosed 2026-10-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2026-10-06 transaction · row 1 1 source row Row 1 · 2026-10-06 · Disposition to issuer · Disposed 57,995 · Balance 0 F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.

ST JUDE MEDICAL, LLC

Report date January 04, 2017 · Filed January 06, 2017

Section 16 reporting ended · disclosed 2017-01-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2017-01-04 transaction · row 1 1 source row Row 1 · 2017-01-04 · Disposition to issuer · Disposed 8,732 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.96 · Expires 2019-12-12	Direct	Reported balance After 2017-01-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-01-04 · Disposition to issuer · Disposed 1,383 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.27 · Expires 2020-12-10	Direct	Reported balance After 2017-01-04 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-01-04 · Disposition to issuer · Disposed 14,749 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.41 · Expires 2021-12-10	Direct	Reported balance After 2017-01-04 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-01-04 · Disposition to issuer · Disposed 13,380 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.08 · Expires 2022-12-08	Direct	Reported balance After 2017-01-04 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2017-01-04 · Disposition to issuer · Disposed 19,616 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.62 · Expires 2023-12-07	Direct	Reported balance After 2017-01-04 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2017-01-04 · Disposition to issuer · Disposed 25,464 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2017-01-04 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2017-01-04 · Disposition to issuer · Disposed 401 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2017-01-04 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2017-01-04 · Disposition to issuer · Disposed 1,114 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2017-01-04 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2017-01-04 · Disposition to issuer · Disposed 2,028 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock.

F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.

F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.

F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 04, 2017 Filed Jan 6, 2017 13:13 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Disposition to issuerStock Options (Right to Buy) · Derivative	14,749	Not disclosed Strike: $35.27	Not disclosed	Disclosure SEC source: 0001179110-17-000588 · edgar.xml · derivative · entry 3 Ellingson Rachel · CIK 0001557271 · VP, Global Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,749 shares Expires 2020-12-10 F2 · price: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. Read SEC document
January 04, 2017 Filed Jan 6, 2017 13:13 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Disposition to issuerStock Options (Right to Buy) · Derivative	1,383	Not disclosed Strike: $34.96	Not disclosed	Disclosure SEC source: 0001179110-17-000588 · edgar.xml · derivative · entry 2 Ellingson Rachel · CIK 0001557271 · VP, Global Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,383 shares Expires 2019-12-12 F2 · price: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. Read SEC document
January 04, 2017 Filed Jan 6, 2017 13:13 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Disposition to issuerCommon Stock	8,732	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-17-000588 · edgar.xml · nonDerivative · entry 1 Ellingson Rachel · CIK 0001557271 · VP, Global Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock. Read SEC document
December 17, 2016 Filed Dec 20, 2016 16:58 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Exercise / conversionRestricted Stock Units · Derivative	676	$0.00	$0.00	Disclosure SEC source: 0001179110-16-033307 · edgar.xml · derivative · entry 12 Ellingson Rachel · CIK 0001557271 · VP, Global Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,028 Underlying: Common Stock · 2,704 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F6 · derivative.exercise_date: The restricted stock units will vest 25% on December 17th annually beginning the date shown. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document
December 17, 2016 Filed Dec 20, 2016 16:58 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Exercise / conversionRestricted Stock Units · Derivative	557	$0.00	$0.00	Disclosure SEC source: 0001179110-16-033307 · edgar.xml · derivative · entry 11 Ellingson Rachel · CIK 0001557271 · VP, Global Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,114 Underlying: Common Stock · 1,671 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F6 · derivative.exercise_date: The restricted stock units will vest 25% on December 17th annually beginning the date shown. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document
December 17, 2016 Filed Dec 20, 2016 16:58 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Exercise / conversionRestricted Stock Units · Derivative	401	$0.00	$0.00	Disclosure SEC source: 0001179110-16-033307 · edgar.xml · derivative · entry 10 Ellingson Rachel · CIK 0001557271 · VP, Global Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401 Underlying: Common Stock · 802 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F6 · derivative.exercise_date: The restricted stock units will vest 25% on December 17th annually beginning the date shown. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document
December 17, 2016 Filed Dec 20, 2016 16:58 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Exercise / conversionRestricted Stock Units · Derivative	698	$0.00	$0.00	Disclosure SEC source: 0001179110-16-033307 · edgar.xml · derivative · entry 9 Ellingson Rachel · CIK 0001557271 · VP, Global Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 698 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F6 · derivative.exercise_date: The restricted stock units will vest 25% on December 17th annually beginning the date shown. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document
December 17, 2016 Filed Dec 20, 2016 16:58 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Tax withholdingCommon Stock	228	$79.20	$18,057.60	Disclosure SEC source: 0001179110-16-033307 · edgar.xml · nonDerivative · entry 8 Ellingson Rachel · CIK 0001557271 · VP, Global Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,732 F5 · shares: 676 shares of restricted stock vested on December 17, 2016. 228 shares were used to pay taxes and 448 shares were released. Read SEC document
December 17, 2016 Filed Dec 20, 2016 16:58 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Exercise / conversionCommon Stock	676	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-16-033307 · edgar.xml · nonDerivative · entry 7 Ellingson Rachel · CIK 0001557271 · VP, Global Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,960 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document
December 17, 2016 Filed Dec 20, 2016 16:58 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Tax withholdingCommon Stock	188	$79.20	$14,889.60	Disclosure SEC source: 0001179110-16-033307 · edgar.xml · nonDerivative · entry 6 Ellingson Rachel · CIK 0001557271 · VP, Global Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,284 F4 · shares: 557 shares of restricted stock vested on December 17, 2016. 188 shares were used to pay taxes and 369 shares were released. Read SEC document
December 17, 2016 Filed Dec 20, 2016 16:58 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Exercise / conversionCommon Stock	557	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-16-033307 · edgar.xml · nonDerivative · entry 5 Ellingson Rachel · CIK 0001557271 · VP, Global Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document
December 17, 2016 Filed Dec 20, 2016 16:58 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Tax withholdingCommon Stock	135	$79.20	$10,692.00	Disclosure SEC source: 0001179110-16-033307 · edgar.xml · nonDerivative · entry 4 Ellingson Rachel · CIK 0001557271 · VP, Global Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,915 F3 · shares: 401 shares of restricted stock vested on December 17, 2016. 135 shares were used to pay taxes and 266 shares were released. Read SEC document
December 17, 2016 Filed Dec 20, 2016 16:58 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Exercise / conversionCommon Stock	401	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-16-033307 · edgar.xml · nonDerivative · entry 3 Ellingson Rachel · CIK 0001557271 · VP, Global Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document
December 17, 2016 Filed Dec 20, 2016 16:58 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Tax withholdingCommon Stock	235	$79.20	$18,612.00	Disclosure SEC source: 0001179110-16-033307 · edgar.xml · nonDerivative · entry 2 Ellingson Rachel · CIK 0001557271 · VP, Global Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,649 F2 · shares: 698 shares of restricted stock vested on December 17, 2016. 235 shares were used to pay taxes and 463 shares were released. Read SEC document
December 17, 2016 Filed Dec 20, 2016 16:58 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Exercise / conversionCommon Stock	698	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-16-033307 · edgar.xml · nonDerivative · entry 1 Ellingson Rachel · CIK 0001557271 · VP, Global Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.